Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$6.52 USD
+0.38 (6.19%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $6.55 +0.03 (0.46%) 7:08 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Syros Pharmaceuticals, Inc. [SYRS]
Reports for Purchase
Showing records 101 - 120 ( 222 total )
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Catching Up with CDK7 - Highlights from Our KOL Call with Dr. Young
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
A New Leader in CDK Inhibition - Let''s Have a KOL Put It into Perspective
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Downgrading to NEUTRAL, Wait to Watch in the Fourth Quarter
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Mark Alles Joins the Board of Directors of Syros.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Enters Partnership With GBT - Sounds Like a Perfect Match to Us
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE-The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Update: Syros Dribbles to the Goal Line With Steady Progress
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Early Discovery Program Ventures Into Sickle Cell Disease
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Syros Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q19 Update: Syros Dribbles to the Goal Line With Steady Progress
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z